Pfizer Ventures and M Ventures led a $32.5m Series B round in Enara Bio.

Pfizer Ventures and M Ventures, two venture capital funds, led a $32.5m Series B round in Enara Bio, a cancer immunotherapies developer, with participation from RA Capital, Samsara BioCapital and SV Health Investors. “Despite major breakthroughs in cancer immunotherapy over the last decade, only a minority of patients with solid tumors receive durable benefit from existing treatments. Dark Antigens may unlock the potential of immunotherapy for many additional patients with solid tumors, and we are pleased to support Enara’s development of this cutting-edge platform to discover and validate these previously untapped targets,” Rana Al-Hallaq, Pfizer Ventures Partner.